ArticleRevista colombiana de obstetricia y ginecologia2026
Prevalence of Hepatitis B, Hepatitis C, and HTLV-1 Using an Expanded Testing Panel Among Pregnant Women in Two Cities in Colombia, 2024-2025
Article in Revista colombiana de obstetricia y ginecologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To estimate the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and human T-cell lymphotropic virus type 1 (HTLV-1) infection using an expanded panel among pregnant women in two Colombian cities, 2024-2025. Material and methods: A descriptive crosssectional study was conducted among pregnant women attending three primary care institutions in Cali and Buenaventura. Participants were selected through consecutive sampling. A total of 320 women were assessed for eligibility; 305 provided informed consent, completed a structured questionnaire, had complete samples, and were included in the final analysis. The panel included hepatitis B surface antigen, antibodies against hepatitis B surface antigen and total core antigen, antibodies against HCV with confirmation by viral RNA, and antibodies against HTLV-1 with confirmation by Western blot. A descriptive analysis was performed, and period prevalence estimates were calculated. Results: The median age was 26 years, and the median gestational age was 22 weeks. Five cases of HTLV-1 infection (1.6 %) and two cases of active HCV infection (0.7 %) were confirmed. For HBV, 214 women were susceptible (70.2 %), 84 had vaccine-induced immunity (27.5 %), 4 had resolved infection (1.3 %), 2 had reactivated chronic infection (0.7 %), and 1 had acute infection (0.3 %). Conclusion: The expanded panel allowed estimation of the prevalence of HBV, HCV, and HTLV-1. The high susceptibility to HBV highlights the need to strengthen vaccination status assessment and hepatitis B vaccination during prenatal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.